All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Lymphoma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2018-12-26T15:06:26.000Z

ASH 2018 | Phase III results from R-CHOP and ibrutinib in untreated non-GCB DLBCL patients

Dec 26, 2018
Share:

Bookmark this article

On Monday 3 December 2018, Oral Session 626 took place at the 60th American Society of Hematology (ASH) Annual Meeting, San Diego, CA. During that session, Abstract #784 was presented by Anas Younes from Memorial Sloan Kettering Cancer Center, New York, NY, USA.

A global, randomized, double-blind, placebo-controlled phase III trial took place, investigating the efficacy of ibrutinib plus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in previously-untreated patients with non-germinal center B-cell-like (non-GCB) diffuse large B-cell lymphoma (DLBCL). The primary endpoint of the study was event-free survival (EFS) in the intention-to-treat (ITT) non-GCB population and the ABC subgroup. Secondary endpoints, included progression-free survival (PFS), complete response (CR) rate, overall survival (OS), and safety.

Study design & baseline characteristics

  • N = 838 previously untreated non-GCB DLBCL patients with stage II−IV disease, Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2, and revised International Prognostic Index (R-IPI) ≥ 1
  • Median age = 62 years; 58.5% of patients were < 65 years old
  • Patients were randomized 1:1 to either of the following regimens:
    • R-CHOP (6-8 cycles) and placebo (n = 419) [R-CHOP + pl]
    • R-CHOP (6-8 cycles) and ibrutinib (n = 419) [R-CHOP + ibr]
  • Dosing:
    • R-CHOP: pre-specified by site
    • Ibrutinib: 560 mg
  • Similar number of patients with ABC subtype in both arms (77.0% vs8% for R-CHOP + ibr vs R-CHOP + pl)
  • Slightly more patients ≥ 65 years in the ibrutinib + R-CHOP arm
  • Median follow-up = 34.8 months
  • Median time from diagnosis to treatment = 27 days

Results

  • R-CHOP + ibr did not improve EFS in patients with non-GCB DLBCL (HR = 0.934; 95% CI, 0.726−200; P = 0.5906)
  • R-CHOP + ibr did not improve EFS in patients with ABC DLBCL (HR = 0.949; 95% CI, 0.704−279; P = 0.7311)
  • Overall response rate (ITT population):
    • R-CHOP + ibr: 89.3%
    • R-CHOP + pl: 93.1%
    • No statistical difference in overall response rate between the two arms
  • CR rates (ITT population):
    • R-CHOP + ibr: 67.3%
    • R-CHOP + pl: 68%
    • No statistical difference in overall response rate between the two arms
  • Central nervous system progression was observed in 2.4% (n = 10) of patients in the R-CHOP + ibr group and in 3.8% (n = 16) in the R-CHOP + pl group
  • Patient age demonstrated significant interaction with treatment for all efficacy outcomes (EFS, PFS, and OS):
    • Significant risk reduction in EFS (30%), PFS (33%), and OS (43%) was observed for patients in the R-CHOP + ibr arm, who were younger than 60 years
    • A similar trend was also observed for the ABC subtype patients (HR = 0.532; 95% CI, 0.307−922 for EFS; HR = 0.345; 95% CI, 0.138−0.862 for OS)
  • More patients in the R-CHOP + pl group received subsequent anti-lymphoma therapy (25.2% vs5%)

Safety

  • Grade ≥ 3 adverse events (AEs) occurred in:
    • R-CHOP + ibr: 89.9%
    • R-CHOP + pl: 87.1%
  • AEs were similar across arms for both age groups
  • Serious AEs were greater in the R-CHOP + ibr group (53.1%), when compared to the R-CHOP + pl group (34.0%), with febrile neutropenia and pneumonia being the two most common AEs for R-CHOP discontinuation
  • Treatment-related AEs (TEAEs) were consistent with those expected for R-CHOP and ibrutinib
  • Higher rates of serious AEs and AEs leading to treatment discontinuation occurred in older patients (≥ 60 years) with R-CHOP + ibr
  • Prophylactic granulocyte-colony stimulating factor (G-CSF) was used in 66.1% of patient in the R-CHOP + ibr arm vs9% in the R-CHOP + pl arm:
    • In patients < 60 years: 56.5% (R-CHOP + ibr) vs2% (R-CHOP + pl)
    • In patients ≥ 60 years: 71.8% (R-CHOP + ibr) vs0% (R-CHOP + pl)
  • In the safety population, treatment exposure was reduced in the R-CHOP + ibr arm, when compared to the R-CHOP + pl group
  • This reduced treatment exposure in the R-CHOP + ibr arm was primarily observed in older patients (≥ 60 years)

Conclusions

  • In the ITT population, R-CHOP + ibr did not improve efficacy in patients with untreated non-GCB DLBCL patients
  • The benefit-risk profile of R-CHOP + ibr is age-dependent:
    • In patients ≥ 60 years, R-CHOP + ibr increased serious AEs and AEs leading to treatment discontinuation
    • In patients < 60 years, R-CHOP + ibr was associated with prolonged EFS, PFS, and OS
  • In older patients (≥ 60 years) the addition of ibrutinib to R-CHOP outweighs the benefits
  1. Younes A. et al. A Global, Randomized, Placebo-Controlled, Phase 3 Study of Ibrutinib Plus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (RCHOP) in Patients with Previously Untreated Non-Germinal Center B-Cell-like (GCB) Diffuse Large B-Cell Lymphoma (DLBCL). Oral Session 626, Abstract #784: ASH 60th Annual Meeting and Exposition, December 2018, San Diego, CA

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you

Newsletter

Subscribe to get the best content related to lymphoma & CLL delivered to your inbox